◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › T › TVTX

Travere Therapeutics Inc (TVTX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-16

Travere Therapeutics Inc (TVTX) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 497 employees. Its market capitalization is roughly $6 billion. In the fiscal year ended 2025-12-31, TVTX reported $491M in revenue and ($26M) in net income.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.

Interactive charts & full statements → Open the TVTX valuation workbench →

TVTX Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Total Revenue	$592M	$491M	$233M	$145M	$109M	$132M	$198M	$175M	$164M	$155M	$134M	$100M	$28M	—	—	—	—
Gross Profit	$557M	$480M	$225M	$134M	$105M	$128M	$192M	$170M	$159M	$151M	$129M	$98M	$28M	—	—	—	—
Gross Margin %	94.1%	97.9%	96.7%	92.1%	96.0%	97.1%	96.9%	97.0%	96.6%	97.7%	96.6%	97.8%	98.0%	—	—	—	—
Operating Income (EBIT)	($40M)	($63M)	($324M)	($388M)	($320M)	($199M)	($176M)	($100M)	($80M)	($54M)	($58M)	($51M)	($80M)	($24M)	($30M)	$0M	$0M
Operating Margin %	-6.8%	-12.8%	-138.9%	-267.2%	-292.2%	-151.3%	-88.8%	-56.9%	-48.7%	-34.7%	-43.6%	-50.8%	-283.0%	—	—	—	—
Net Income	($43M)	($26M)	($322M)	($111M)	($278M)	($180M)	($169M)	($146M)	($103M)	($60M)	($48M)	$117M	($111M)	($34M)	($30M)	$0M	$0M
Net Margin %	-7.3%	-5.2%	-137.9%	-76.7%	-254.4%	-136.6%	-85.4%	-83.5%	-62.5%	-38.6%	-35.9%	117.4%	-393.4%	—	—	—	—
EBITDA	$1M	$22M	($266M)	($326M)	($299M)	($184M)	($145M)	($107M)	($73M)	($39M)	($39M)	$129M	($74M)	($14M)	($30M)	$0M	$0M
Earnings Per Share (EPS)	$-0.49	$-0.29	$-4.08	$-1.50	$-4.37	$-3.01	$-3.56	$-3.46	$-2.54	$-1.54	$-1.25	$3.12	$-4.43	$-2.38	$-2.84	$-0.00	$-0.00
Shares Outstanding (M)	93M	89M	79M	74M	64M	60M	48M	42M	40M	39M	38M	38M	25M	14M	11M	—	96M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TVTX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$170M	$127M	$130M	$165M	$114M	$82M	$75M	$63M
Gross Profit	$167M	$100M	$127M	$163M	$113M	$77M	$72M	$61M
Gross Margin %	98.7%	79.0%	98.0%	99.0%	98.7%	94.3%	96.6%	97.4%
Operating Income (EBIT)	$4M	($37M)	($32M)	$25M	($13M)	($43M)	($61M)	($56M)
Operating Margin %	2.3%	-29.0%	-25.0%	15.1%	-11.1%	-52.2%	-81.2%	-89.3%
Net Income	($35M)	($37M)	$3M	$26M	($13M)	($41M)	($60M)	($55M)
Net Margin %	-20.5%	-29.2%	2.1%	15.6%	-11.1%	-50.4%	-80.6%	-87.1%
EBITDA	($33M)	($9M)	($1M)	$44M	$4M	($26M)	($45M)	($41M)
Earnings Per Share (EPS)	$-0.37	$-0.40	$0.03	$0.25	$-0.14	$-0.47	$-0.73	$-0.70
Shares Outstanding (M)	93M	92M	90M	103M	89M	88M	83M	78M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TVTX Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Cash from Operations (CFO)	$93M	$38M	($237M)	($280M)	($186M)	($15M)	($43M)	($58M)	($25M)	$7M	($2M)	($1M)	($46M)	($18M)	($3M)	$0M	$0M
Capital Expenditures (CapEx)	$63M	$58M	$101M	$42M	$28M	$24M	$120M	$16M	$20M	$14M	$12M	$7M	$4M	$6M	$1M	$0M	$0M
Free Cash Flow (FCF)	$29M	($20M)	($339M)	($322M)	($215M)	($39M)	($163M)	($74M)	($45M)	($7M)	($14M)	($8M)	($50M)	($23M)	($4M)	$0M	$0M
FCF Margin %	4.9%	-4.2%	-145.2%	-221.4%	-196.1%	-29.5%	-82.0%	-42.1%	-27.2%	-4.3%	-10.1%	-7.6%	-176.6%	—	—	—	—
Dividends Paid	—	—	—	—	—	—	—	—	—	—	—	—	$94M	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TVTX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$58M	($40M)	$61M	$14M	$5M	($42M)	($36M)	($43M)
Capital Expenditures (CapEx)	$22M	$22M	$19M	$0M	$0M	$12M	$10M	$8M
Free Cash Flow (FCF)	$36M	($63M)	$42M	$14M	$5M	($54M)	($45M)	($51M)
FCF Margin %	21.2%	-49.2%	32.2%	8.6%	4.2%	-66.0%	-60.6%	-80.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TVTX Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Total Assets	$799M	$605M	$594M	$789M	$673M	$777M	$607M	$605M	$709M	$520M	$525M	$512M	$135M	$20M	$2M	$0M	$0M
Cash & Cash Equivalents	$118M	$93M	$59M	$58M	$62M	$166M	$85M	$62M	$103M	$99M	$41M	$38M	$18M	$6M	$0M	$0M	$0M
Total Liabilities	$775M	$490M	$535M	$588M	$630M	$475M	$396M	$384M	$391M	$227M	$218M	$212M	$173M	$39M	$6M	$0M	$0M
Total Debt (Short + Long-Term)	$609M	$318M	$384M	$382M	$380M	$230M	$216M	$207M	$218M	$45M	$0M	$0M	$40M	$1M	$1M	$0M	$0M
Total Shareholders' Equity	$25M	$115M	$59M	$201M	$43M	$302M	$211M	$221M	$318M	$293M	$308M	$300M	($37M)	($18M)	($3M)	$0M	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TVTX viewer.

Other Companies in BIOTECHNOLOGY

RYTM · Rhythm Pharmaceuticals Inc — $7 billion
CGON · CG Oncology, Inc. Common stock — $7 billion
ORKA · Oruka Therapeutics, Inc. — $6 billion
MIRM · Mirum Pharmaceuticals Inc — $6 billion
SRRK · Scholar Rock Holding Corp — $6 billion
LGND · Ligand Pharmaceuticals Incorporated — $6 billion
CRSP · Crispr Therapeutics AG — $5 billion
COGT · Cogent Biosciences Inc — $5 billion

← TVTODAY All “T” companies TVVISION →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.